2023-05-11 09:51:16 ET
- Instil Bio press release ( NASDAQ: TIL ): Q1 GAAP EPS of -$0.44.
-
As of March 31, 2023, Instil had cash, cash equivalents, restricted cash and marketable securities of $223.9 million, which consists of $27.4 million in cash and cash equivalents, $0.7 million in restricted cash and $195.8 million in marketable securities, compared to $260.9 million in total cash and cash equivalents and marketable securities, consisting of $43.7 million in cash and cash equivalents and $217.2 million in marketable securities as of December 31, 2022.
-
Instil expects that its cash, cash equivalents and marketable securities as of March 31, 2023 will enable it to fund its operating plan beyond 2026.
-
Research and development expenses were $20.7 million for the three months ended March 31, 2023, compared to $39.2 million for the three months ended March 31, 2022.
For further details see:
Instil Bio GAAP EPS of -$0.44